Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 165

1.

Avatrombopag, an Alternate Treatment Option to Reduce Platelet Transfusions in Patients with Thrombocytopenia and Chronic Liver Disease-Integrated Analyses of 2 Phase 3 Studies.

Poordad F, Terrault NA, Alkhouri N, Tian W, Allen LF, Rabinovitz M.

Int J Hepatol. 2020 Jan 25;2020:5421632. doi: 10.1155/2020/5421632. eCollection 2020.

2.

Comparison between non-alcoholic fatty liver disease screening guidelines in children and adolescents.

Ezaizi Y, Kabbany MN, Conjeevaram Selvakumar PK, Sarmini MT, Singh A, Lopez R, Nobili V, Alkhouri N.

JHEP Rep. 2019 Jul 9;1(4):259-264. doi: 10.1016/j.jhepr.2019.06.005. eCollection 2019 Oct.

3.

Noninvasive Testing Using Magnetic Resonance Imaging Techniques as Outcomes in Nonalcoholic Steatohepatitis Clinical Trials: How Full Is the Glass?

Noureddin N, Schattenberg JM, Alkhouri N, Noureddin M.

Hepatol Commun. 2020 Feb 3;4(2):141-144. doi: 10.1002/hep4.1473. eCollection 2020 Feb. No abstract available.

4.

NASH and NAFLD: emerging drugs, therapeutic targets and translational and clinical challenges.

Alkhouri N.

Expert Opin Investig Drugs. 2020 Feb;29(2):87. doi: 10.1080/13543784.2020.1721169. Epub 2020 Jan 29. No abstract available.

PMID:
31984804
5.

Increased Prevalence of Obesity and Metabolic Syndrome in Patients with Alcoholic Fatty Liver Disease.

Singh A, Amin H, Garg R, Gupta M, Lopez R, Alkhouri N, MCCullough A.

Dig Dis Sci. 2020 Jan 24. doi: 10.1007/s10620-020-06056-1. [Epub ahead of print]

PMID:
31981110
6.

Nonalcoholic fatty liver disease (NAFLD) and nonalcoholic steatohepatitis (NASH): prevalence, therapeutic innovations, and stumbling blocks for clinical development.

Alkhouri N.

Expert Opin Investig Drugs. 2020 Feb;29(2):115-116. doi: 10.1080/13543784.2020.1721167. Epub 2020 Feb 3. No abstract available.

PMID:
31971024
7.

Fibroblast growth factor (FGF)-21 based therapies: A magic bullet for nonalcoholic fatty liver disease (NAFLD)?

Ritchie M, Hanouneh IA, Noureddin M, Rolph T, Alkhouri N.

Expert Opin Investig Drugs. 2020 Feb;29(2):197-204. doi: 10.1080/13543784.2020.1718104. Epub 2020 Jan 22. Review.

PMID:
31948295
8.

Cenicriviroc for the treatment of liver fibrosis in adults with nonalcoholic steatohepatitis: AURORA Phase 3 study design.

Anstee QM, Neuschwander-Tetri BA, Wong VW, Abdelmalek MF, Younossi ZM, Yuan J, Pecoraro ML, Seyedkazemi S, Fischer L, Bedossa P, Goodman Z, Alkhouri N, Tacke F, Sanyal A.

Contemp Clin Trials. 2019 Dec 24;89:105922. doi: 10.1016/j.cct.2019.105922. [Epub ahead of print]

9.

Thyromimetics as emerging therapeutic agents for nonalcoholic steatohepatitis: rationale for the development of resmetirom (MGL-3196).

Alkhouri N.

Expert Opin Investig Drugs. 2020 Feb;29(2):99-101. doi: 10.1080/13543784.2020.1708899. Epub 2019 Dec 25. No abstract available.

PMID:
31868036
10.

Designing Clinical Trials in Pediatric Nonalcoholic Steatohepatitis: Tips for Patient Selection and Appropriate Endpoints.

Alkhouri N, Kohli R, Feldstein AE.

Hepatol Commun. 2019 Nov 8;3(12):1563-1570. doi: 10.1002/hep4.1449. eCollection 2019 Dec.

11.

Trends in pioglitazone use among U.S. adults with type 2 diabetes and suspected nonalcoholic fatty liver disease.

Le P, Chaitoff A, Rothberg MB, McCullough A, Alkhouri N.

Expert Opin Investig Drugs. 2020 Feb;29(2):205-208. doi: 10.1080/13543784.2020.1704731. Epub 2019 Dec 24.

PMID:
31829750
12.

Effects of Belapectin, an Inhibitor of Galectin-3, in Patients with Nonalcoholic Steatohepatitis With Cirrhosis And Portal Hypertension.

Chalasani N, Abdelmalek MF, Garcia-Tsao G, Vuppalanchi R, Alkhouri N, Rinella M, Noureddin M, Pyko M, Shiffman M, Sanyal A, Allgood A, Shlevin H, Horton R, Zomer E, Irish W, Goodman Z, Harrison SA, Traber PG.

Gastroenterology. 2019 Dec 5. pii: S0016-5085(19)41895-7. doi: 10.1053/j.gastro.2019.11.296. [Epub ahead of print]

13.

Characterization of patients with both alcoholic and nonalcoholic fatty liver disease in a large United States cohort.

Khoudari G, Singh A, Noureddin M, Fritze D, Lopez R, Asaad I, Lawitz E, Poordad F, Kowdley KV, Alkhouri N.

World J Hepatol. 2019 Oct 27;11(10):710-718. doi: 10.4254/wjh.v11.i10.710.

14.

Resmetirom (MGL-3196) for the treatment of non-alcoholic steatohepatitis: a multicentre, randomised, double-blind, placebo-controlled, phase 2 trial.

Harrison SA, Bashir MR, Guy CD, Zhou R, Moylan CA, Frias JP, Alkhouri N, Bansal MB, Baum S, Neuschwander-Tetri BA, Taub R, Moussa SE.

Lancet. 2019 Nov 30;394(10213):2012-2024. doi: 10.1016/S0140-6736(19)32517-6. Epub 2019 Nov 11.

PMID:
31727409
15.

Insulin sensitizer MSDC-0602K in non-alcoholic steatohepatitis: A randomized, double-blind, placebo-controlled phase IIb study.

Harrison SA, Alkhouri N, Davison BA, Sanyal A, Edwards C, Colca JR, Lee BH, Loomba R, Cusi K, Kolterman O, Cotter G, Dittrich HC.

J Hepatol. 2019 Nov 4. pii: S0168-8278(19)30650-6. doi: 10.1016/j.jhep.2019.10.023. [Epub ahead of print]

PMID:
31697972
16.

GS-0976 (Firsocostat): an investigational liver-directed acetyl-CoA carboxylase (ACC) inhibitor for the treatment of non-alcoholic steatohepatitis (NASH).

Alkhouri N, Lawitz E, Noureddin M, DeFronzo R, Shulman GI.

Expert Opin Investig Drugs. 2020 Feb;29(2):135-141. doi: 10.1080/13543784.2020.1668374. Epub 2019 Sep 19. Review.

PMID:
31519114
17.

Screening for Nonalcoholic Fatty Liver Disease in the Primary Care Clinic.

Pandyarajan V, Gish RG, Alkhouri N, Noureddin M.

Gastroenterol Hepatol (N Y). 2019 Jul;15(7):357-365.

18.

Provider Attitudes and Practice Patterns for Direct-Acting Antiviral Therapy for Patients With Hepatocellular Carcinoma.

Rich NE, Yang JD, Perumalswami PV, Alkhouri N, Jackson W, Parikh ND, Mehta N, Salgia R, Duarte-Rojo A, Kulik L, Rakoski M, Said A, Oloruntoba O, Ioannou GN, Hoteit MA, Moon AM, Rangnekar AS, Eswaran SL, Zheng E, Jou JH, Hanje J, Pillai A, Hernaez R, Wong R, Scaglione S, Samant H, Kapuria D, Chandna S, Rosenblatt R, Ajmera V, Frenette CT, Satapathy SK, Mantry P, Jalal P, John BV, Fix OK, Leise M, Lindenmeyer CC, Flores A, Patel N, Jiang ZG, Latt N, Dhanasekaran R, Odewole M, Kagan S, Marrero JA, Singal AG.

Clin Gastroenterol Hepatol. 2019 Jul 26. pii: S1542-3565(19)30786-4. doi: 10.1016/j.cgh.2019.07.042. [Epub ahead of print]

PMID:
31357028
19.

Trends in Prevalence of Nonalcoholic Fatty Liver Disease in US Adults with Prediabetes.

Le P, Chaitoff A, Rothberg MB, Alkhouri N, McCullough A.

J Gen Intern Med. 2019 Nov;34(11):2336-2338. doi: 10.1007/s11606-019-05163-8. No abstract available.

PMID:
31325127
20.

Pediatric cholestatic liver disease: Successful transition of care.

Selvakumar PK, Hupertz V, Mittal N, Kowdley KV, Alkhouri N.

Cleve Clin J Med. 2019 Jul;86(7):454-464. doi: 10.3949/ccjm.86a.18140. Review.

21.

NAFLD in children: new genes, new diagnostic modalities and new drugs.

Nobili V, Alisi A, Valenti L, Miele L, Feldstein AE, Alkhouri N.

Nat Rev Gastroenterol Hepatol. 2019 Sep;16(9):517-530. doi: 10.1038/s41575-019-0169-z. Epub 2019 Jul 5. Review.

PMID:
31278377
22.

Noninvasive Tests Accurately Identify Advanced Fibrosis due to NASH: Baseline Data From the STELLAR Trials.

Anstee QM, Lawitz EJ, Alkhouri N, Wong VW, Romero-Gomez M, Okanoue T, Trauner M, Kersey K, Li G, Han L, Jia C, Wang L, Chen G, Subramanian GM, Myers RP, Djedjos CS, Kohli A, Bzowej N, Younes Z, Sarin S, Shiffman ML, Harrison SA, Afdhal NH, Goodman Z, Younossi ZM.

Hepatology. 2019 Nov;70(5):1521-1530. doi: 10.1002/hep.30842. Epub 2019 Aug 19.

PMID:
31271665
23.

Real-world observational experience with direct-acting antivirals for hepatitis C: baseline resistance, efficacy, and need for long-term surveillance.

Loo N, Hanysak B, Mann J, Ramirez R, Kim J, Mitchell R, Van Frank T, Guerrero R, Hinojosa K, Christensen K, Pedicone LD, Alkhouri N, Wells J, Landaverde C, Rodas F, Lawitz E, Poordad F.

Medicine (Baltimore). 2019 Jun;98(26):e16254. doi: 10.1097/MD.0000000000016254.

24.

Awareness of Nonalcoholic Fatty Liver Disease Is Increasing but Remains Very Low in a Representative US Cohort.

Singh A, Dhaliwal AS, Singh S, Kumar A, Lopez R, Gupta M, Noureddin M, Carey W, McCullough A, Alkhouri N.

Dig Dis Sci. 2019 Jun 11. doi: 10.1007/s10620-019-05700-9. [Epub ahead of print]

PMID:
31187324
25.

Ombitasvir/paritaprevir/ritonavir + dasabuvir +/- ribavirin in real world hepatitis C patients.

Loo N, Lawitz E, Alkhouri N, Wells J, Landaverde C, Coste A, Salcido R, Scott M, Poordad F.

World J Gastroenterol. 2019 May 14;25(18):2229-2239. doi: 10.3748/wjg.v25.i18.2229.

26.

Looking Into the Crystal Ball: Predicting the Future Challenges of Fibrotic NASH Treatment.

Alkhouri N, Lawitz E, Noureddin M.

Hepatol Commun. 2019 Mar 28;3(5):605-613. doi: 10.1002/hep4.1342. eCollection 2019 May. Review.

27.

Hepatocellular carcinoma surveillance in the 21st century: Saving lives or causing harm?

Hanouneh IA, Alkhouri N, Singal AG.

Clin Mol Hepatol. 2019 Sep;25(3):264-269. doi: 10.3350/cmh.2019.1001. Epub 2019 Mar 4. Review.

28.

An Update on the Pharmacological Treatment of Nonalcoholic Fatty Liver Disease: Beyond Lifestyle Modifications.

Alkhouri N, Scott A.

Clin Liver Dis (Hoboken). 2018 Apr;11(4):82-86. doi: 10.1002/cld.708. No abstract available.

29.

Lean Nonalcoholic Fatty Liver Disease: Should It Be Considered in Lean Adolescents With Elevated Liver Enzymes?

Conjeevaram Selvakumar PK, Kabbany MN, Alkhouri N.

J Pediatr Gastroenterol Nutr. 2019 Feb;68(2):e40-e41. doi: 10.1097/MPG.0000000000002214. No abstract available.

PMID:
30672769
30.

Clinical Practice Approach to Nonalcoholic Fatty Liver Disease by Pediatric Gastroenterologists in the United States.

Shapiro WL, Yu EL, Arin JC, Murray KF, Ali S, Desai NK, Xanthakos SA, Lin HC, Alkhouri N, Abdou R, Abrams SH, Butler MW, Faasse SA, Gillis LA, Hadley TA, Jain AK, Kavan M, Kordy K, Lee P, Panganiban J, Pohl JF, Potter C, Rudolph B, Sundaram SS, Joshi S, Proudfoot JA, Goyal NP, Harlow KE, Newton KP, Schwimmer JB.

J Pediatr Gastroenterol Nutr. 2019 Feb;68(2):182-189. doi: 10.1097/MPG.0000000000002194.

PMID:
30640271
31.

Lean NAFLD: Should it be considered in Lean Adolescents with Elevated Liver Enzymes?

Selvakumar PKC, Kabbany MN, Alkhouri N.

J Pediatr Gastroenterol Nutr. 2018 Nov 27. doi: 10.1097/MPG.0000000000002214. [Epub ahead of print] No abstract available.

PMID:
30499885
32.

Non-alcoholic fatty liver disease: a pandemic disease with multisystem burden.

Albhaisi S, Issa D, Alkhouri N.

Hepatobiliary Surg Nutr. 2018 Oct;7(5):389-391. doi: 10.21037/hbsn.2018.07.01. No abstract available.

33.

New insights into genetic predisposition and novel therapeutic targets for nonalcoholic fatty liver disease.

Barbara M, Scott A, Alkhouri N.

Hepatobiliary Surg Nutr. 2018 Oct;7(5):372-381. doi: 10.21037/hbsn.2018.08.05. Review.

34.

Population-Based Trends in Prevalence of Nonalcoholic Fatty Liver Disease in US Adults With Type 2 Diabetes.

Le P, Chaitoff A, Rothberg MB, McCullough A, Gupta NM, Alkhouri N.

Clin Gastroenterol Hepatol. 2019 Oct;17(11):2377-2378. doi: 10.1016/j.cgh.2018.11.023. Epub 2018 Nov 17.

PMID:
30458246
35.

Characteristics and Outcomes of Liver Transplantation for Primary Biliary Cholangitis in Young Patients: Analysis of the United Network for Organ Sharing Database.

Singh A, Fritze D, Mansouri M, Lopez R, Poordad F, Lawitz E, Cigarroa F, Halff G, Alkhouri N.

Transplantation. 2019 Jun;103(6):1191-1198. doi: 10.1097/TP.0000000000002501.

PMID:
30376552
36.

Correction: Serum Wisteria floribunda agglutinin-positive Mac-2-binding protein levels predict the presence of fibrotic nonalcoholic steatohepatitis (NASH) and NASH cirrhosis.

Alkhouri N, Johnson C, Adams L, Kitajima S, Tsuruno C, Colpitts TL, Hatcho K, Lawitz E, Lopez R, Feldstein AE.

PLoS One. 2018 Oct 4;13(10):e0205541. doi: 10.1371/journal.pone.0205541. eCollection 2018.

37.

Overview of Updated Practice Guidelines for Pediatric Nonalcoholic Fatty Liver Disease.

Shah J, Okubote T, Alkhouri N.

Gastroenterol Hepatol (N Y). 2018 Jul;14(7):407-414.

38.

Serum Wisteria floribunda agglutinin-positive Mac-2-binding protein levels predict the presence of fibrotic nonalcoholic steatohepatitis (NASH) and NASH cirrhosis.

Alkhouri N, Johnson C, Adams L, Kitajima S, Tsuruno C, Colpitts TL, Hatcho K, Lawitz E, Lopez R, Feldstein AE.

PLoS One. 2018 Aug 30;13(8):e0202226. doi: 10.1371/journal.pone.0202226. eCollection 2018. Erratum in: PLoS One. 2018 Oct 4;13(10):e0205541.

39.

Management of nonalcoholic fatty liver disease: Lessons learned from type 2 diabetes.

Alkhouri N, Poordad F, Lawitz E.

Hepatol Commun. 2018 Jun 7;2(7):778-785. doi: 10.1002/hep4.1195. eCollection 2018 Jul. Review.

40.

NASH Leading Cause of Liver Transplant in Women: Updated Analysis of Indications For Liver Transplant and Ethnic and Gender Variances.

Noureddin M, Vipani A, Bresee C, Todo T, Kim IK, Alkhouri N, Setiawan VW, Tran T, Ayoub WS, Lu SC, Klein AS, Sundaram V, Nissen NN.

Am J Gastroenterol. 2018 Nov;113(11):1649-1659. doi: 10.1038/s41395-018-0088-6. Epub 2018 Jun 8.

PMID:
29880964
41.

Nonalcoholic Fatty Liver Disease in Children: Not a Small Matter.

Conjeevaram Selvakumar PK, Kabbany MN, Alkhouri N.

Paediatr Drugs. 2018 Aug;20(4):315-329. doi: 10.1007/s40272-018-0292-2. Review.

PMID:
29740791
42.

Acetyl-CoA Carboxylase Inhibitor GS-0976 for 12 Weeks Reduces Hepatic De Novo Lipogenesis and Steatosis in Patients With Nonalcoholic Steatohepatitis.

Lawitz EJ, Coste A, Poordad F, Alkhouri N, Loo N, McColgan BJ, Tarrant JM, Nguyen T, Han L, Chung C, Ray AS, McHutchison JG, Subramanian GM, Myers RP, Middleton MS, Sirlin C, Loomba R, Nyangau E, Fitch M, Li K, Hellerstein M.

Clin Gastroenterol Hepatol. 2018 Dec;16(12):1983-1991.e3. doi: 10.1016/j.cgh.2018.04.042. Epub 2018 Apr 26.

PMID:
29705265
43.

Prevalence of Suspected Nonalcoholic Fatty Liver Disease in Lean Adolescents in the United States.

Conjeevaram Selvakumar PK, Kabbany MN, Lopez R, Rayas MS, Lynch JL, Alkhouri N.

J Pediatr Gastroenterol Nutr. 2018 Jul;67(1):75-79. doi: 10.1097/MPG.0000000000001974.

PMID:
29570139
44.

Tacrolimus and Mycophenolate Mofetil as Second-Line Therapies for Pediatric Patients with Autoimmune Hepatitis.

Efe C, Taii HA, Ytting H, Aehling N, Bhanji RA, Hagström H, Purnak T, Muratori L, Werner M, Muratori P, Klintman D, Schiano TD, Montano-Loza AJ, Berg T, Larsen FS, Alkhouri N, Ozaslan E, Heneghan MA, Yoshida EM, Wahlin S.

Dig Dis Sci. 2018 May;63(5):1348-1354. doi: 10.1007/s10620-018-5011-x. Epub 2018 Mar 22.

PMID:
29569003
45.

The search for noninvasive methods to identify liver fibrosis in children with nonalcoholic fatty liver disease.

Mandelia C, Kabbany MN, Conjeevaram Selvakumar PK, Alkhouri N.

Biomark Med. 2018 Mar;12(3):265-273. doi: 10.2217/bmm-2017-0038. Epub 2018 Mar 8. Review.

PMID:
29517271
46.

The utility of noninvasive scores in assessing the prevalence of nonalcoholic fatty liver disease and advanced fibrosis in type 1 diabetic patients.

Singh A, Le P, Lopez R, Alkhouri N.

Hepatol Int. 2018 Jan;12(1):37-43. doi: 10.1007/s12072-017-9840-z. Epub 2018 Jan 9.

PMID:
29318450
47.

Nonalcoholic fatty liver disease and hepatocellular carcinoma: new insights on presentation and natural history.

Issa D, Alkhouri N.

Hepatobiliary Surg Nutr. 2017 Dec;6(6):401-403. doi: 10.21037/hbsn.2017.07.07. No abstract available.

48.

Novel treatments for chronic hepatitis C: closing the remaining gaps.

Alkhouri N, Lawitz E, Poordad F.

Curr Opin Pharmacol. 2017 Dec;37:107-111. doi: 10.1016/j.coph.2017.10.001. Epub 2017 Nov 6. Review.

PMID:
29121533
49.

Nonalcoholic Steatohepatitis is the Most Rapidly Increasing Indication for Liver Transplantation in Young Adults in the United States.

Doycheva I, Issa D, Watt KD, Lopez R, Rifai G, Alkhouri N.

J Clin Gastroenterol. 2018 Apr;52(4):339-346. doi: 10.1097/MCG.0000000000000925.

PMID:
28961576
50.

Accuracy of Noninvasive Fibrosis Scores in Predicting the Presence of Fibrosis in Patients after Liver Transplantation.

Kabbany MN, Conjeevaram Selvakumar PK, Guirguis J, Rivas J, Akras Z, Lopez R, Hanouneh I, Eghtesad B, Alkhouri N.

Exp Clin Transplant. 2018 Oct;16(5):562-567. doi: 10.6002/ect.2016.0340. Epub 2017 Sep 26.

Supplemental Content

Loading ...
Support Center